Background: Influenza is a zoonotic disease that infects millions of people each year resulting in hundreds of thousands of deaths, and in turn devastating pandemics.
| INTRODUC TI ON
Influenza A viruses (IAVs) circulate in waterfowl as their natural reservoir and are categorized based on the antigenic properties of their hemagglutinin (HA) and neuraminidase (NA) proteins. There are 16 different HAs and nine different NA present in wild birds. 1 Frequently, wild birds infect poultry resulting in the culling of millions of birds and significant economic losses. However, wild birds rarely show disease symptoms while IAV in poultry usually exhibits respiratory tropism and is able to mutate into a more highly pathogenic form. 2 Influenza is also a zoonotic disease, and the virus is occasionally transmitted from infected poultry to humans. Certain HA/ NA combinations, however, seem to be more favorable for human infections. H1N1, H2N2, and H3N2 have caused several devastating outbreaks in humans in the past such as the 1918 "Spanish flu," the 1957 "Asian pandemic," the 1968 "Hong Kong pandemic," and the 2009 "Swine flu," respectively. 3 Currently, the recently emerged H7N9 strain is of concern for global public health. Low-pathogenic avian influenza (LPAI) H7N9 was first discovered in humans in 2013 in China when three patients were hospitalized with severe and fatal influenza. 4 Since then, there have been six epidemic H7N9 waves that resulted in 1567 laboratory-confirmed human infections and 615 deaths and a seventh wave is currently ongoing. 5 Intriguingly, the virus isolated from the 2013 outbreak was suggested to be derived from chickens that did not show any (or only very mild) symptoms of disease. Further investigations revealed that the viral genes were exclusively from avian origin. 4 To this date, there are no reports of H7N9 human to human transmissions even though it cannot be excluded in very few cases.
However, most cases of human H7N9 infections were attributed to exposure of humans to infected wild birds or poultry and live animal markets. 5 A crucial step in the life cycle of H7N9 (and all other influenza subtypes) is the cleavage of its HA fusion protein by host proteases.
HA is synthesized as a precursor and requires proteolytic processing to exert its fusogenic activity. Cleavage occurs at the C-terminus of the fusion peptide and results in its exposure allowing HA to induce fusion of the viral and cellular membrane and subsequent release of the RNA into the host cell. 6, 7 LPAI viruses have a monobasic cleavage site that consists of a single arginine, which is preceded by three amino acids that are influenza subtype-specific. While LPAI viruses in wild birds are usually cleaved by trypsin in their gastro-intestinal tract, there are trypsin-like serine proteases in humans and poultry that reside in the respiratory tract and which are able to process these viruses. Therefore, the disease is usually confined to this tissue. 8 Only very little is known about the activation of H7N9 viruses. Previously, it was reported that the type II transmembrane serine protease TMPRSS2 plays a role in the cleavage of H7N9 HA and activation of the virus in mice. 9, 10 Both studies showed that TMPRSS2 knockout (KO) mice were highly tolerant to H7N9 infections. When KO mice were complemented with human or mouse TMPRSS2, their susceptibility to the virus was restored. 9 We recently reported that human matriptase/ST 14 was able to very efficiently cleave a H7N9 cleavage motif peptide mimic. 11 Matriptase/ST 14 is a membrane-bound protease localized in epithelial cells of various tissues in humans that seems to play a significant role in the activation of various influenza A subtypes such H1N1 and H9N2. 12, 13 However, results obtained using cleavage site peptide mimics do not always reflect the in vivo situation and need to be validated. 11, 14 Here, we show that human matriptase/ST 14 cleaves H7N9 HA resulting in a fusogenic active protein. We further demonstrate that matriptase/ST 14 promotes the infectivity of pseudoparticles carrying H7N9. Ultimately, we provide data showing the activation of A/ Shanghai/2/2013 virus by human matriptase/ST 14 leading to a high infectivity in cell culture. Together, our data suggest that matriptase/ ST 14 is a novel protease in the human respiratory tract that promotes H7N9 infection. The pCMV-MLVgag-pol murine leukemia virus (MLV) packaging construct, the pTG-Luc transfer vector encoding luciferase reporter, and pCAGGS/VSV-G plasmid were described before. 15, 16 Recombinant human matriptase/ST 14 was purchased from R&D systems. The specific activity of the enzyme is described as 10 000 pmol/min/µg for the fluorogenic peptide substrate Boc-QAR-AMC.
| MATERIAL S AND ME THODS

| Cells, viruses, plasmids and protease
| Matriptase/ST 14 cleavage experiment and western blot analysis
293T cells were grown in 6-well plates and transfected with pDZ/ H7N9 HA and pDZ/H7N9 NA using Turbofect according to the manufacturer's recommendations (Invitrogen). Eighteen hours post-transfection, cells were washed with PBS, and 200 nM matriptase/ST 14 in matriptase buffer (20 mM Tris, 10 mM CaCl 2 , 150 mM NaCl, pH 7.4) was added to one well and incubated on a rocker at 37°C and 5% CO 2 for 90 minutes. For the control, 0.8 mM Trypsin in PBS was added for 10 minutes. Cells were then processed for Western blot analysis as previously described. 12 The antibody to detect A/Shanghai/2/2013 H7N9 HA (NR48765) was obtained from the Biodefense and Emerging Infections Research Resources Repository. The secondary antibody had an Alexa fluor 488 tag and was purchased from Invitrogen. Western blot membranes were scanned using a ChemiDoc imaging system (Bio-Rad) to facilitate exposure in a linear range. Bands were quantified using ImageJ software, and cleavage efficiencies for HA 1 were calculated by the following equation: (HA 1 /[HA 0 + HA 1 ])*100. Graph was generated using Graphpad Prism 7 software. 
| Cell-cell fusion assay
| Pseudoparticle production and infection
For pseudoparticle production, 293T cells were grown in 6-well plates and transfected with pDZ/H7N9 HA, pDZ/H7N9 NA, pCMV-MLVgag-pol, and pTG-Luc using Turbofect according to the manufacturer's recommendations. Controls were transfected with pCAGGS/VSV-G, pCMV-MLVgag-pol, and pTG-Luc (positive control) or only pCMV-MLVgag-pol and pTG-Luc (negative control). Supernatants were harvested 72 hours post-transfection, and pseudoparticles were stored at −80°C. Infections, cell lysis, and data analysis were performed as previously described. 17 Experiment was repeated three independent times. Results were plotted, and statistical analysis was conducted using Graphpad Prism7 software. immuno-plaque assay as previously described. 18 The experiment was repeated three independent times. Data and statistical analysis were performed using Graphpad Prism7 software.
| Virus infections and quantification
| RE SULTS
| H7N9 HA is cleaved by human matriptase/ST 14 and results in a fusogenic active protein
We previously reported that recombinant human matriptase/ ST 14 cleaved a fluorogenic peptide mimicking the cleavage site motif of A/Shanghai/2/2013 H7N9 HA very efficiently. 11 Unlike the situation with other human-specific proteases tested, the resulting Vmax value for matriptase/ST 14 was not significantly different from trypsin, which served as a positive control. However, control. We did not observe any cleavage of H7N9 HA without protease, and very efficient cleavage when trypsin was added ( Figure 1A) . Recombinant human matriptase/ST 14 cleaved H7N9, too, but to a lesser extent than trypsin ( Figure 1A ). Quantification revealed that trypsin converted about 80% of HA 0 into HA 1 and matriptase/ST 14 proteolytically processed about 30% HA 0 into HA 1 (Figure 1B ).
Next, we were interested to see whether matriptase/ST 14-mediated cleavage of H7N9 HA results in a fusogenic active protein.
Therefore, we expressed H7N9 HA in VERO cells and incubated the cells subsequently with recombinant human matriptase/ST 14 for three hours. Controls were as described above. The negative control without added protease did not show cell fusion ( Figure 2 ).
However, when trypsin and matriptase/ST 14 were added to cells expressing H7N9 HA, strong syncytia formation was observed ( Figure 2 ).
In conclusion, recombinant human matriptase/ST 14 proteolytically processes H7N9 HA that is then able to exert its fusogenic activity.
| Viral entry is facilitated by matriptase/ST 14 cleaved H7N9 HA
After we established that recombinant human matriptase/ST 14-mediated cleavage of results in a fusogenic H7N9 HA protein, we wanted to test whether it would promote the infectivity of the virus. As a first step, we chose to produce pseudoparticles representing surrogates of native virions that allowed us to study the viral entry into host cells. The pseudoparticles used in this assay possess a MLV core that incorporates a luciferase reporter gene upon their release from the producing cells. 17 To facilitate fusion, the pseudovirions contained H7N9 HA and were incubated with trypsin or matriptase/ST 14 prior to their addition to cells. We used two negative controls: (a) pseudoparticles with H7N9 HA but Pseudoparticles carrying VSV-G were highly infective showing that the pseudoparticle production worked as expected ( Figure 3A , Table 1A ). H7N9 HA pseudovirions treated with trypsin and with matriptase/ST 14 were significantly more infectious compared to the same pseudoparticles without protease treatment ( Figure 3B , Table 1A ). However, there was no significant difference between trypsin-and matriptase/ST 14-treated pseudoparticles suggesting that all pseudovirions were depleted ( Figure 1B , Table 1A ).
Pseudoparticles without an incorporated fusion protein were not infectious. The data show that matriptase/ST 14-mediated cleavage of H7N9 HA results in fully infectious virions that are able to fuse with host cells.
| Matriptase/ST 14 promotes viral growth of A/ Shanghai/2/2013 H7N9
Next, we investigated whether matriptase/ST 14 was able to sustain and promote viral growth of A/Shanghai/2/2013 H7N9 in a cell culture system. Therefore, we infected MDCK cells with the live virus at a low MOI of 0.1 and added trypsin or matriptase/ST 14. The control did not receive protease treatment. After 48 hours, the supernatants were collected, and the viral titers were quantified using an immunoplaque assay.
Influenza A/Shanghai/2/2013 H7N9 that was not treated with a protease exhibited a titer of about 1 × 10 4 pfu/mL (Figure 4 , Table 1B ).
Virus that was treated with trypsin and matriptase/ST 14, however, had significantly higher titers of approximately 5 × 10 10 pfu/mL and 1.7 × 10 7 , respectively ( Figure 4 , Table 1B ).
F I G U R E 2
Analysis of H7N9 HA-triggered cell-cell fusion. Immunofluorescence staining of H7N9 HA without protease treatment and with trypsin and matriptase/ST 14 treatment. Single cells and syncytia-forming cells are emphasized with a white dashed line. H7N9 HA was labeled with a specific 1st HA antibody and a secondary Alexa Fluor 488 antibody. Nuclei were stained with DAPI. Magnification of the images is 25×
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Together, our data suggest that human matriptase/ST 14 can cleave H7N9 HA and may significantly contribute viral growth of influenza A/Shanghai/2/2013 H7N9 in humans.
| D ISCUSS I ON
Influenza H7N9 viruses have caused a significant number of causalities since their emergence in 2013 and pose a major threat for public health because of their ability to continuously evolve and reassort. 5 This is well-illustrated by the finding that H7N9 viruses from the 5th wave were antigenically distinct from the viruses that emerged in 2013, rendering existing candidate vaccines ineffective. 19 Novel approaches to fight influenza infections include targeting host proteases that are responsible for the activation of the virus. [20] [21] [22] A major benefit of this approach is that it is very unlikely to lead to resistance phenotypes in the virus. However, it requires the information by which proteases distinct influenza HA subtypes are proteolytically activated.
So far, the type II transmembrane serine protease TMPRSS2 is the only human protease that has been associated with the activation of LPAI H7N9 HA. 9 We recently showed that matriptase/ST 14 cleaved a peptide representing the H7N9 LPAI HA cleavage motif very efficiently using an assay with fluorogenic peptides representing different HA subtype cleavage site mimics. A limitation of this assay is that peptides may produce false-positive results because the structural interaction between protease and cleavage site might be altered compared to the full-length HA protein. Matriptase/ST 14, for example, was reported to proteolytically process the A/ Aichi/2/68 H3N2 HA cleavage site motif in peptide assays. 12, 14 When matriptase/ST 14 was then tested with the A/Aichi/2/68 H3N2 HA full-length protein expressed in cells, only little cleavage that did not produce fusogenic HA or no cleavage was observed.
Here we demonstrate that human matriptase/ST 14 cleaves H7N9
HA expressed in cells resulting in a fully fusogenic active protein validating our results from the previously published peptide assay.
Matriptase/ST 14-mediated cleavage of H7N9 HA also promoted the infectivity of pseudovirions and A/Shanghai/2/2013 virus in cell culture. Our data indicate that human matriptase/ST 14 is a relevant protease to cause LPAI H7N9 infectivity in humans and may represent an important pathogenicity determinant and target for therapeutic intervention.
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